Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$5.75 -2.4%	$6.05	$3.93 ▼ $7.32	$301.31M	1.51	697,142 shs	750,706 shs
ABUS Arbutus Biopharma	$3.14 -3.1%	$3.35	$2.71 ▼ $4.73	$620.55M	1.2	959,688 shs	608,992 shs
ARCT Arcturus Therapeutics	$13.36 -3.0%	$12.48	$8.04 ▼ $25.88	$373.72M	2.27	421,219 shs	428,993 shs
NATR Nature's Sunshine Products	$16.02 +2.8%	$14.37	$10.81 ▼ $18.06	$287.84M	1.14	51,232 shs	168,196 shs
THTX Theratechnologies	$3.17 -0.9%	$2.62	$1.12 ▼ $3.20	$147.14M	0.55	880,339 shs	4.94 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	0.00%	+2.68%	-12.40%	+30.91%	+30.04%
ABUS Arbutus Biopharma	0.00%	+3.35%	-7.04%	+7.48%	+3.69%
ARCT Arcturus Therapeutics	0.00%	+2.29%	+6.61%	+50.00%	-36.43%
NATR Nature's Sunshine Products	0.00%	+7.38%	+7.31%	+35.75%	+4.64%
THTX Theratechnologies	0.00%	+33.19%	+21.32%	+90.85%	+120.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABEO Abeona Therapeutics	3.9754 of 5 stars	3.5	2.0	0.0	4.5	1.8	2.5	0.0
ABUS Arbutus Biopharma	1.4422 of 5 stars	3.5	0.0	0.0	0.0	0.0	2.5	0.6
ARCT Arcturus Therapeutics	3.727 of 5 stars	4.6	2.0	0.0	0.0	3.2	2.5	0.6
NATR Nature's Sunshine Products	1.8253 of 5 stars	2.5	3.0	0.0	0.0	2.7	2.5	0.0
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	3.00	Buy	$19.25	234.78% Upside
ABUS Arbutus Biopharma	3.00	Buy	$5.50	75.16% Upside
ARCT Arcturus Therapeutics	3.11	Buy	$54.00	304.19% Upside
NATR Nature's Sunshine Products	3.00	Buy	$18.33	14.44% Upside
THTX Theratechnologies	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest ARCT, ABUS, ABEO, NATR, and THTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	THTX Theratechnologies	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$32.00 ➝ $35.00
6/3/2025	NATR Nature's Sunshine Products	DA Davidson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00
6/2/2025	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$19.00
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/16/2025	ABEO Abeona Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $20.00
5/15/2025	ABEO Abeona Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $66.00

(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$3.50M	84.05	N/A	N/A	$1.01 per share	5.69
ABUS Arbutus Biopharma	$6.17M	97.47	N/A	N/A	$0.51 per share	6.16
ARCT Arcturus Therapeutics	$152.31M	2.38	N/A	N/A	$8.90 per share	1.50
NATR Nature's Sunshine Products	$454.36M	0.65	$1.28 per share	12.48	$8.71 per share	1.84
THTX Theratechnologies	$85.87M	1.70	N/A	N/A	($0.55) per share	-5.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	-$63.73M	-$1.27	N/A	N/A	N/A	N/A	-118.82%	-52.48%	8/11/2025 (Estimated)
ABUS Arbutus Biopharma	-$69.92M	-$0.41	N/A	N/A	N/A	-1,196.64%	-75.51%	-55.81%	8/7/2025 (Estimated)
ARCT Arcturus Therapeutics	-$80.94M	-$2.53	N/A	N/A	N/A	-47.47%	-27.41%	-19.01%	8/4/2025 (Estimated)
NATR Nature's Sunshine Products	$7.70M	$0.53	30.23	∞	N/A	2.22%	6.98%	4.63%	8/6/2025 (Estimated)
THTX Theratechnologies	-$8.31M	-$0.08	N/A	45.29	N/A	-4.18%	N/A	-0.37%	7/9/2025 (Estimated)

Latest ARCT, ABUS, ABEO, NATR, and THTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2025	Q2 2025	ARCT Arcturus Therapeutics	-$1.11	N/A	N/A	N/A	$17.64 million	N/A
5/15/2025	Q1 2025	ABEO Abeona Therapeutics	-$0.35	-$0.24	+$0.11	-$0.24	N/A	N/A
5/14/2025	Q1 2025	ABUS Arbutus Biopharma	-$0.09	-$0.13	-$0.04	-$0.13	$2.54 million	$1.76 million
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/6/2025	Q1 2025	NATR Nature's Sunshine Products	$0.16	$0.25	+$0.09	$0.25	$109.39 million	$113.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
NATR Nature's Sunshine Products	N/A	N/A	N/A	N/A	N/A
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.27	4.90	4.90
ABUS Arbutus Biopharma	0.04	6.01	6.01
ARCT Arcturus Therapeutics	0.06	5.64	5.64
NATR Nature's Sunshine Products	N/A	2.41	1.50
THTX Theratechnologies	N/A	1.08	0.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
ABUS Arbutus Biopharma	43.79%
ARCT Arcturus Therapeutics	94.54%
NATR Nature's Sunshine Products	79.40%
THTX Theratechnologies	N/A

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	5.40%
ABUS Arbutus Biopharma	20.30%
ARCT Arcturus Therapeutics	15.30%
NATR Nature's Sunshine Products	5.60%
THTX Theratechnologies	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	90	51.16 million	48.40 million	Optionable
ABUS Arbutus Biopharma	90	191.53 million	152.65 million	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.97 million	Optionable
NATR Nature's Sunshine Products	850	18.46 million	17.43 million	Optionable
THTX Theratechnologies	140	45.98 million	N/A	Optionable

ARCT, ABUS, ABEO, NATR, and THTX Headlines

Recent News About These Companies

Theratechnologies: Beyond GLP-1s - Is Tesamorelin's Exit A Sign Of New Metabolic Opportunities?

July 7 at 1:19 PM | seekingalpha.com

Theratechnologies (NASDAQ:THTX) Stock Rating Lowered by Jones Trading

July 5 at 2:01 AM | americanbankingnews.com

Future Pak to buy Theratechnologies for $254 million

July 4 at 10:42 AM | thepharmaletter.comT

Theratechnologies Stock (NASDAQ:THTX), Insider Trading Activity

July 3, 2025 | benzinga.com

Theratechnologies Inc. (THTX) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

Theratechnologies Stock Short Interest Report | NASDAQ:THTX - Benzinga

July 3, 2025 | benzinga.com

Theratechnologies shareholders should take the deal, Research Capital says

July 3, 2025 | cantechletter.comC

Theratechnologies to be bought by CB Biotechnology for $254M

July 3, 2025 | msn.com

Theratechnologies to Announce Second Quarter 2025 Financial Results

July 3, 2025 | globenewswire.com

Theratechnologies' (THTX) Hold Rating Reaffirmed at Jones Trading

July 3, 2025 | marketbeat.com

Theratechnologies to be Acquired by Future Pak Affiliate

July 2, 2025 | tipranks.com

Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

July 2, 2025 | finance.yahoo.com

Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

July 2, 2025 | globenewswire.com

Theratechnologies Reports on its Annual Meeting of Shareholders

May 29, 2025 | globenewswire.com

Theratechnologies announces annual shareholder meeting

May 4, 2025 | uk.investing.com

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

May 2, 2025 | globenewswire.com

Theratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 Offer

April 18, 2025 | seekingalpha.com

Is Theratechnologies Inc. (THTX) the Best Rising Penny Stock to Buy According to Analysts?

April 18, 2025 | msn.com

Theratechnologies to further evaluate potential sale of the company

April 16, 2025 | markets.businessinsider.com

Theratechnologies Provides Update on Sale Process

April 15, 2025 | financialpost.comF

Theratechnologies Provides Update on Sale Process

April 15, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT, ABUS, ABEO, NATR, and THTX Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$5.75 -0.14 (-2.38%)

Closing price 04:00 PM Eastern

Extended Trading

$5.79 +0.04 (+0.70%)

As of 05:59 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Arbutus Biopharma NASDAQ:ABUS

$3.14 -0.10 (-3.09%)

Closing price 04:00 PM Eastern

Extended Trading

$3.16 +0.02 (+0.67%)

As of 07:56 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Arcturus Therapeutics NASDAQ:ARCT

$13.36 -0.42 (-3.05%)

Closing price 04:00 PM Eastern

Extended Trading

$13.44 +0.08 (+0.60%)

As of 07:57 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Nature's Sunshine Products NASDAQ:NATR

$16.02 +0.43 (+2.76%)

As of 04:00 PM Eastern

Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.

Theratechnologies NASDAQ:THTX

$3.17 -0.03 (-0.94%)

Closing price 04:00 PM Eastern

Extended Trading

$3.16 -0.02 (-0.47%)

As of 07:59 PM Eastern

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time